In the BioHarmony Drug Report Database
Ibalizumab
Trogarzo (ibalizumab) is an antibody pharmaceutical. Ibalizumab was first approved as Trogarzo on 2018-03-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against T-cell surface glycoprotein CD4.
Trade Name
|
Trogarzo |
|---|---|
Common Name
|
ibalizumab |
ChEMBL ID
|
CHEMBL1743029 |
Indication
|
hiv infections |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
